top of page

Search Results

Search this site

658 results found with an empty search

  • FDA approves Lisraya as first oral treatment for adults with dermatomyositis

    Priovant’s once-daily JAK/TYK2 inhibitor introduces a new FDA-approved treatment option for the rare autoimmune disease, supported by Phase III evidence of improvements across muscle, skin and physical-function measures. The US Food and Drug Administration (FDA) has approved Lisraya (brepocitinib) 30 mg tablets for the treatment of dermatomyositis in adults, making it the first FDA-approved oral therapy specifically indicated for the disease. The approval is supported by a 241-patient Phase III trial in which once-daily Lisraya produced greater improvement in the study’s composite Total Improvement Score at week 52 than placebo and also improved physical function and skin disease activity. Field Content Alert Type Drug Approval Drug Name Lisraya (brepocitinib) Indication Treatment of dermatomyositis in adults Therapy Area(s) Immunology; Rheumatology; Dermatology; Rare disease Geography United States (FDA) What Happened On 27 August 2026, the FDA approved Lisraya (brepocitinib) for adults with dermatomyositis. Lisraya is a once-daily oral JAK/TYK2 inhibitor designed to block signalling pathways involved in immune and inflammatory responses. The approval was granted to Priovant Therapeutics and follows FDA Orphan Drug and Priority Review designations. (U.S. Food and Drug Administration) Why It Matters Dermatomyositis is a rare autoimmune disease characterised by chronic inflammation, progressive muscle weakness and distinctive skin manifestations. Patients have historically relied substantially on corticosteroids, immunosuppressants and other therapies not specifically approved for the disease. Lisraya therefore provides a specifically approved oral treatment and introduces JAK/TYK2 inhibition as a new therapeutic approach for adult dermatomyositis. (U.S. Food and Drug Administration) Supporting Context Approval was supported by a Phase III randomised, double-blind, placebo-controlled study involving 241 adults. Patients received brepocitinib 30 mg, 15 mg or placebo for 52 weeks. The approved 30 mg dose achieved a higher average Total Improvement Score (TIS) at week 52 than placebo, with improvements also observed in physical function and skin disease activity. Patients receiving the 30 mg dose were also more likely to reduce corticosteroid use by week 48. (U.S. Food and Drug Administration) Safety Common adverse reactions included upper respiratory tract infection, headache, fatigue, urinary tract infection and nausea. Lisraya carries a boxed warning covering serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events and thrombosis. (U.S. Food and Drug Administration) Key Takeaway Lisraya becomes the first FDA-approved oral therapy specifically for adult dermatomyositis, adding a targeted JAK/TYK2 inhibitor to a treatment landscape that has historically depended heavily on corticosteroids and other immunosuppressive approaches. What to Watch Uptake of Lisraya in clinical practice, particularly its positioning relative to existing immunosuppressive treatment strategies and whether its ability to reduce corticosteroid use translates into a meaningful longer-term treatment advantage. Primary Source US Food and Drug Administration Relevant Date 27 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Gilead’s Bixlenvo as single-tablet HIV option for patients on complex regimens

    The once-daily combination of bictegravir and lenacapavir offers virologically suppressed adults a new route to simplify treatment, including patients previously requiring complex multi-tablet regimens. The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) as a complete regimen for adults with HIV-1 who are virologically suppressed on stable antiretroviral therapy and have no known or suspected resistance to its individual components. Bixlenvo becomes the first and only single-tablet regimen for most virologically suppressed patients on complex HIV treatment regimens who cannot use currently available single-tablet options, combining bictegravir with the first-in-class capsid inhibitor lenacapavir. Field Content Alert Type Drug Approval Drug Name Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) Indication Complete regimen to replace current antiretroviral therapy in adults with HIV-1 who are virologically suppressed, with HIV-1 RNA below 50 copies/mL, on a stable regimen and with no known or suspected resistance to Bixlenvo’s individual components Therapy Area(s) Infectious disease; HIV Geography United States (FDA) What Happened On 27 August 2026, the FDA approved Gilead’s Bixlenvo, a once-daily single-tablet combination of bictegravir and lenacapavir. The treatment pairs bictegravir, an integrase strand transfer inhibitor (INSTI), with lenacapavir, a first-in-class capsid inhibitor with no cross-resistance to existing antiretroviral classes. Bixlenvo requires a two-day initiation regimen involving oral Sunlenca (lenacapavir), followed by one Bixlenvo tablet daily from day three onwards. (Gilead Sciences Investor Relations) Why It Matters Single-tablet HIV regimens have simplified treatment for many patients, but some people with resistance, tolerability issues, contraindications or drug interactions still require complex combinations. Bixlenvo provides a new simplification option for virologically suppressed adults, including treatment-experienced patients who previously required multiple tablets or more than once-daily dosing. (Gilead Sciences Investor Relations) Supporting Context Approval was supported by the Phase III ARTISTRY-1 and ARTISTRY-2 trials. Both showed Bixlenvo was comparable to the control regimens in maintaining virologic suppression through week 48. ARTISTRY-1 specifically studied highly treatment-experienced patients: participants had been treated for a median 28 years, 67% had historical NRTI resistance and some were taking as many as 11 pills per day before switching. (Gilead) Safety Bixlenvo was generally well tolerated in the ARTISTRY programme, with no significant or new safety concerns identified. The most commonly reported adverse reactions were headache, nausea and diarrhoea. (Gilead Sciences Investor Relations) Key Takeaway Bixlenvo extends the benefits of once-daily single-tablet HIV therapy to a broader group of virologically suppressed adults, particularly treatment-experienced patients whose resistance or treatment history has previously required more complicated antiretroviral regimens. What to Watch Uptake among treatment-experienced patients and further expansion of Gilead’s lenacapavir-based HIV portfolio. Gilead and Merck are separately developing islatravir/lenacapavir as a once-weekly oral HIV regimen, with Phase III studies having maintained virologic suppression through week 48 and regulatory submissions planned. (Gilead Sciences Investor Relations) Primary Source Gilead Sciences Relevant Date 27 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for 2026–2027 season

    The updated Comirnaty formulation targets the XFG variant and will begin shipping immediately for eligible older adults and people aged five to 64 at increased risk of severe COVID-19. The US Food and Drug Administration (FDA) has approved Pfizer and BioNTech’s XFG-adapted Comirnaty COVID-19 vaccine for the 2026–2027 season in adults aged 65 and older and people aged five to 64 with at least one underlying condition that increases their risk of severe COVID-19. The updated mRNA vaccine targets the XFG variant in line with FDA guidance and is expected to become available through US pharmacies, hospitals and clinics within days. Field Content Alert Type Vaccine Approval Product Name Comirnaty XFG (COVID-19 Vaccine, mRNA) Indication Prevention of COVID-19 in adults aged 65 years and older, and individuals aged 5–64 years with at least one underlying condition that puts them at high risk for severe COVID-19 outcomes Therapy Area(s) Infectious disease; Vaccines; COVID-19 Geography United States (FDA) What Happened On 27 August 2026, the FDA approved the supplemental Biologics License Application for Pfizer and BioNTech’s 2026–2027 XFG-adapted Comirnaty vaccine. The monovalent formulation targets the XFG variant and replaces the previous season’s LP.8.1-adapted formulation. Pfizer and BioNTech said shipments would begin immediately, with the vaccine expected in pharmacies, hospitals and clinics across the US within days. (Pfizer) Why It Matters COVID-19 vaccines are periodically adapted as the virus evolves. The FDA selected XFG as its preferred vaccine composition for the 2026–2027 US season, meaning this approval aligns Comirnaty more closely with contemporary circulating SARS-CoV-2 variants ahead of the autumn respiratory-virus season. (Pfizer) Supporting Context The approval draws on the cumulative clinical, non-clinical and real-world evidence supporting Comirnaty, together with manufacturing, quality and non-clinical data for the updated formulation. Pfizer and BioNTech reported that the XFG-adapted vaccine generated strong immune responses against circulating variants including XFG, XFG.1.1, NB.1.8.1, PQ.17 and PQ.2.8.1. More than five billion doses of Pfizer-BioNTech COVID-19 vaccines have been distributed globally. (Pfizer) Key Takeaway FDA approval establishes Pfizer and BioNTech’s XFG-adapted Comirnaty as their US COVID-19 vaccine for the 2026–2027 season, with eligibility focused on people aged 65 and over and younger individuals at increased risk of severe disease. What to Watch The immediate rollout of the XFG-adapted vaccine, US vaccination recommendations and coverage for the 2026–2027 season, and whether future SARS-CoV-2 evolution requires another change in vaccine composition. The same XFG-adapted formulation received European Commission marketing authorisation in July 2026, although the EU authorisation covers individuals from six months of age. (Pfizer) Primary Source Pfizer and BioNTech Relevant Date 27 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA pushes faster generic drug development with 55 new product-specific guidances

    The latest regulatory package is intended to reduce uncertainty, development costs and delays for generic manufacturers as the US government increases pressure to bring lower-cost medicines to patients more quickly. The US Food and Drug Administration (FDA) has published 55 new and revised product-specific guidances (PSGs) designed to accelerate generic drug development and streamline abbreviated new drug application (ANDA) assessment. The initiative forms part of the FDA’s wider Drug Competition Action Plan and the US administration’s efforts to increase pharmaceutical competition and reduce prescription drug costs. Field Content Alert Type Industry Update Topic Generic drug regulation; Drug pricing; Regulatory guidance Organisation(s) US Food and Drug Administration (FDA); Center for Drug Evaluation and Research (CDER) Affected Stakeholders Generic drug manufacturers; branded pharmaceutical companies; ANDA applicants; patients; payers Therapy Area(s) Multiple therapy areas Geography United States What Happened On 21 August 2026, the FDA published a batch of 55 draft product-specific guidances covering the development of generic medicines and the evidence expected to support ANDAs. The package includes 23 new guidances and 32 revisions, with the agency aiming to give developers clearer routes for demonstrating that proposed generics meet FDA requirements. (Life Sciences IP Review) Why It Matters Product-specific guidance can allow generic manufacturers to design development programmes around the FDA’s expectations earlier, potentially avoiding unnecessary studies, deficiencies and repeated review cycles. The intended result is a faster and less costly route to market, particularly for products where technical complexity has historically made generic competition more difficult. (U.S. Food and Drug Administration) Supporting Context The action is part of the FDA’s Drug Competition Action Plan and supports the objectives of Executive Order 14273, Lowering Drug Prices by Once Again Putting Americans First. FDA says it is simultaneously clarifying expectations for generic developers and improving the efficiency and predictability of its own ANDA review processes while maintaining scientific standards. (U.S. Food and Drug Administration) Who Is Most Affected Generic manufacturers stand to benefit directly from greater regulatory clarity and potentially more efficient development programmes. Originator pharmaceutical companies could face earlier or increased competition once patent and exclusivity barriers expire, while patients and payers could benefit if additional generic entrants translate into lower medicine prices. Industry Impact Faster generic development could have significant economic consequences. FDA research estimated that 773 generic drug applications approved during 2023 generated $18.6 billion in savings during the 12 months following approval, including $2.4 billion associated with first-generic entrants. (U.S. Food and Drug Administration) Key Takeaway The FDA is using more detailed product-specific guidance as one of its tools to remove regulatory bottlenecks from generic development, with the broader objective of getting competing medicines to the US market sooner and increasing downward pressure on drug prices. What to Watch Whether the new guidances translate into shorter development and review timelines, particularly for complex generics, and whether the FDA introduces further measures under its Drug Competition Action Plan as the US administration continues its push to reduce prescription drug costs. Primary Source US Food and Drug Administration Relevant Date 21 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Haisco licenses obesity drug HSK47388 to new US biotech in deal worth up to $1.12 billion

    The agreement gives a newly formed company backed by Population Health Partners and ARCH Venture Partners ex-China rights to Haisco’s Phase II-ready oral THR-β agonist for obesity and metabolic disorders. Haisco Pharmaceutical has granted a newly established US biotechnology company founded by Population Health Partners and ARCH Venture Partners exclusive ex-China rights to develop and commercialise HSK47388, an oral thyroid hormone receptor beta (THR-β) agonist being developed for obesity and related metabolic diseases. Haisco will receive $120 million upfront and near-term payments and is eligible for development and commercial milestones that could take total payments above $1.12 billion, plus royalties on future net sales. Field Content Alert Type Deal Companies Haisco Pharmaceutical; newly formed US biotechnology company founded by Population Health Partners and ARCH Venture Partners Deal Type Exclusive licensing agreement Asset or Company HSK47388 Therapy Area(s) Obesity; Metabolic disease Technology or Modality Oral small-molecule thyroid hormone receptor beta (THR-β) agonist Deal Value Haisco will receive $120 million in upfront and near-term payments and is eligible for additional development and commercial milestone payments that could bring total payments to more than $1.12 billion, plus tiered royalties on future net sales. The milestone component is contingent and should not be treated as guaranteed consideration. Development Stage Phase II-ready Geography Worldwide excluding Greater China What Happened On 26 August 2026, Haisco announced an exclusive licensing agreement covering HSK47388 with a newly formed US biotechnology company founded by Population Health Partners and ARCH Venture Partners. The new company receives exclusive rights to develop and commercialise HSK47388 outside Greater China, while Haisco retains rights in Greater China. Haisco will receive $120 million in upfront and near-term payments, with development and commercial milestones potentially taking total payments above $1.12 billion, in addition to royalties on net sales. Why It Matters The agreement moves a China-originated metabolic programme into a separately financed US company backed by experienced life-sciences investors and provides a route for global development outside Greater China. HSK47388 targets THR-β rather than the incretin pathways used by established GLP-1-based obesity medicines, potentially providing a complementary approach to weight management if its early clinical profile is confirmed in larger studies. Supporting Context HSK47388 is a selective oral THR-β agonist designed to increase energy expenditure and improve lipid metabolism while limiting unwanted THR-α-associated effects. Haisco has reported early clinical findings supporting further development in obesity, but the candidate remains investigational and its efficacy and safety require confirmation in later-stage trials. Strategic Rationale The new US company gains exclusive ex-Greater China rights to a Phase II-ready metabolic asset without having to build the programme from discovery, while Haisco receives substantial near-term consideration and retains Greater China rights alongside milestone and royalty participation in international markets. The involvement of Population Health Partners and ARCH Venture Partners provides dedicated capital and development expertise for the programme’s global advancement. Potential Impact If later-stage trials confirm meaningful weight loss and metabolic benefits, HSK47388 could provide a differentiated oral approach within the rapidly expanding obesity market and potentially be evaluated alongside incretin-based therapies. Its eventual clinical and commercial role remains dependent on successful development and regulatory approval. Key Takeaway Haisco’s licensing agreement puts more than $1.12 billion of potential economics behind an ex-China obesity programme built around an oral, non-incretin mechanism. What to Watch Formation and naming of the new US company, initiation of Phase II development for HSK47388 and clinical evidence showing whether THR-β activation can deliver meaningful weight loss with an acceptable safety profile. Primary Source https://en.prnasia.com/releases/global/haisco-enters-into-exclusive-license-agreement-with-new-us-venture-founded-by-population-health-partners-and-arch-venture-partners-545132.shtml Relevant Date 26 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Bristol Myers Squibb ends $380 million Cellares CAR-T manufacturing partnership

    BMS concluded that Cellares’ automated Cell Shuttle platform could not meet the specific requirements for commercial Breyanzi production, prompting Cellares to cut around 100 positions. Bristol Myers Squibb has terminated its manufacturing partnership with Cellares after determining that the Cell Shuttle automated manufacturing system could not meet the requirements necessary to produce commercial batches of its approved CAR-T therapy Breyanzi (lisocabtagene maraleucel). The termination ends a global capacity reservation and supply agreement originally valued at up to $380 million and has led Cellares to plan approximately 100 job cuts as it resizes its operations. Field Content Alert Type Industry Update Topic Cell therapy manufacturing; Partnership termination; Workforce Organisation(s) Bristol Myers Squibb (BMS); Cellares Affected Stakeholders Cellares employees; BMS cell therapy manufacturing operations; CAR-T manufacturing partners Therapy Area(s) Oncology; Haematology; Cell therapy Geography United States What Happened BMS has ended its partnership with Cellares following an evaluation of the Cell Shuttle automated cell therapy manufacturing platform for production of Breyanzi. BMS said the system could not meet the necessary requirements for manufacturing commercial Breyanzi and stressed that its conclusion was specific to Breyanzi and the therapy’s established, regulatory-approved manufacturing process. Cellares said it strongly disagrees with BMS’s characterisation and noted that Cell Shuttle has produced GMP drug product for an FDA-regulated clinical programme. The companies originally entered a global capacity reservation and supply agreement in 2024 valued at up to $380 million. (BioSpace) Why It Matters The termination illustrates the practical difficulty of introducing a different manufacturing platform for an already approved autologous cell therapy with an established regulatory manufacturing process. For Cellares, the loss is commercially significant because BMS represented a major Cell Shuttle partnership; for BMS, the decision means Breyanzi production will continue without the planned Cellares manufacturing route. (BioSpace) Supporting Context Cell Shuttle is designed to automate end-to-end CAR-T manufacturing at clinical and commercial scale. BMS entered the Cellares agreement in 2024 as part of its manufacturing strategy, while Breyanzi has been FDA approved since 2021 and is currently produced through BMS facilities and specialist external manufacturers. (BioSpace) Who Is Most Affected Cellares and its workforce face the most immediate impact. A California WARN filing indicates that the company plans to permanently eliminate approximately 100 positions on 20 October 2026, spanning engineering, commercial operations, recruitment, software and other functions. (BioSpace) Industry Impact The setback highlights a key challenge for cell therapy manufacturing: technologies designed to automate and scale production must still fit the specific manufacturing and regulatory requirements attached to individual therapies. BMS emphasised that its decision relates specifically to Breyanzi, so it should not be interpreted as establishing that Cell Shuttle is unsuitable for other cell therapy programmes. (BioSpace) Key Takeaway BMS’s decision ends a major commercial validation opportunity for Cellares’ automated manufacturing platform and shows the barriers involved in changing production processes for an already approved CAR-T therapy. What to Watch Cellares’ implementation of the approximately 100 planned job cuts, whether the company secures additional commercial-scale manufacturing customers and how its other clinical and commercial Cell Shuttle programmes progress following the loss of BMS. Primary Source Bristol Myers Squibb and Cellares statements reported by BioSpace Relevant Date 26 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • 4basebio and Genezen expand collaboration to advance synthetic DNA for viral vector manufacturing

    The commercial partnership combines 4basebio’s cell-free hpDNA platform with Genezen’s viral vector CDMO capabilities to provide cell and gene therapy developers with an alternative to conventional plasmid DNA manufacturing. 4basebio and Genezen have expanded their non-exclusive collaboration to provide cell and gene therapy developers with access to 4basebio’s synthetic hpDNA technology through Genezen’s viral vector development and manufacturing services. The partnership is intended to support programmes from early development through clinical and commercial manufacturing by combining cell-free DNA production with Genezen’s viral vector process and manufacturing infrastructure. Field Content Alert Type Deal Companies 4basebio; Genezen Deal Type Strategic commercial collaboration Asset or Company 4basebio’s hpDNA synthetic DNA platform integrated with Genezen’s viral vector development and manufacturing services Therapy Area(s) Cell and gene therapy; Genetic medicines Technology or Modality Synthetic cell-free DNA; AAV and other viral vector manufacturing Deal Value Financial terms were not disclosed. Development Stage Platform collaboration supporting programmes from research and early development through clinical and commercial manufacturing Geography Global What Happened On 26 August 2026, 4basebio and Genezen announced an expanded, non-exclusive commercial collaboration giving drug developers access to 4basebio’s Research Use Only, High-Quality and GMP-grade hpDNA through Genezen’s viral vector development and manufacturing services. Genezen will offer 4basebio’s synthetic DNA for viral vector applications, creating an integrated route from DNA starting material through vector manufacturing. The companies did not disclose financial terms or identify individual therapeutic programmes covered by the collaboration. (GlobeNewswire) Why It Matters Plasmid DNA is widely used as a starting material in viral vector production, making its manufacturing timeline, purity, material requirements and scalability relevant to cell and gene therapy development. 4basebio’s enzymatic process produces DNA without bacterial backbone sequences or antibiotic resistance genes and offers Genezen customers an alternative starting material that could streamline vector manufacturing, although programme-level benefits will need to be demonstrated in individual applications. (GlobeNewswire) Supporting Context In AAV production, 4basebio says its hpDNA template has demonstrated titres comparable with plasmid DNA while requiring approximately 30% less DNA mass and transfection reagent. The company also says its cell-free process can shorten DNA production timelines compared with conventional plasmid manufacturing; these performance claims come from 4basebio and should not be interpreted as guaranteed outcomes for every manufacturing programme. (GlobeNewswire) Strategic Rationale 4basebio gains an additional commercial channel for its synthetic DNA technology through an established viral vector CDMO, while Genezen expands the manufacturing options it can offer cell and gene therapy developers. The partnership is designed to allow developers to incorporate synthetic DNA into manufacturing strategies from early development while retaining a route towards GMP and commercial-scale production. (GlobeNewswire) Potential Impact Wider use of cell-free synthetic DNA could reduce dependence on traditional bacterial plasmid manufacturing in some viral vector programmes and potentially improve manufacturing efficiency and scalability. The extent of any benefit will depend on individual vector processes and successful adoption by Genezen customers. Key Takeaway The expanded collaboration integrates 4basebio’s synthetic DNA technology with Genezen’s viral vector CDMO services, giving gene therapy developers another manufacturing route from early development through commercial scale. What to Watch Adoption of hpDNA by Genezen customers, disclosure of specific programmes using the integrated platform and evidence showing whether the reported material and timeline efficiencies translate into clinical and commercial-scale viral vector manufacturing. Primary Source 4basebio / Genezen collaboration announcement Relevant Date 26 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Monod Bio licenses AI-designed protein technologies to SignalChem for drug discovery assays

    The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform. Monod Bio has granted SignalChem Biotech a non-exclusive licence to incorporate its AI-designed LuxSit luciferase technology and NovoBodies into custom luminescent assays and protein-fusion services for third-party research customers. The agreement provides Monod Bio with another commercial channel for its de novo protein-design platform while expanding SignalChem and parent company Sino Biological’s AI-enabled drug discovery and life-science research capabilities. Field Content Alert Type Deal Companies Monod Bio; SignalChem Biotech; Sino Biological Deal Type Non-exclusive technology licensing agreement Asset or Company LuxSit de novo luciferase technology and NovoBodies Therapy Area(s) Drug discovery; Life sciences research; Diagnostics Technology or Modality AI-designed proteins; De novo protein design; Luminescent biosensors; Engineered binding proteins Deal Value Financial terms were not disclosed. SignalChem’s parent company Sino Biological said revenue associated with the business is not expected to have a material impact on its overall financial performance. (PR Newswire) Development Stage Commercial research-use technology platform Geography United States; Canada; Global What Happened On 26 August 2026, Monod Bio and SignalChem Biotech, a wholly owned subsidiary of Sino Biological, announced a non-exclusive licensing agreement covering Monod Bio’s LuxSit de novo luciferase technology and NovoBodies. SignalChem can incorporate the technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. The companies did not disclose financial terms. (PR Newswire) Why It Matters The agreement moves Monod Bio’s AI-designed proteins beyond internal technology development by embedding them within commercial research services available to external drug discovery customers. For SignalChem, the licence adds AI-designed protein components that could support development of specialised assays and discovery tools for complex biological targets. (PR Newswire) Supporting Context LuxSit is an AI-designed luciferase engineered for use in luminescent biosensors, while NovoBodies are compact and highly stable binding proteins designed to recognise different biological targets. Monod Bio develops novel proteins using AI-powered de novo protein design and commercialises the technology through its “Monod Inside” partnership model. (PR Newswire) Strategic Rationale Monod Bio gains access to SignalChem and Sino Biological’s customer base and global life-science services infrastructure without granting exclusive rights to its technologies. SignalChem expands its CRO offering with AI-designed protein capabilities, supporting Sino Biological’s broader strategy of integrating AI-enabled technologies into its research tools and services portfolio. (PR Newswire) Potential Impact The partnership could increase adoption of AI-designed proteins within research assays and discovery workflows by making the technologies accessible through an established CRO provider. Its commercial significance will depend on customer adoption, and Sino Biological has cautioned that the business is not currently expected to have a material impact on its overall financial performance. (PR Newswire) Key Takeaway Monod Bio is using a licensing model to put its AI-designed proteins directly into SignalChem’s commercial discovery services, extending its platform into third-party drug research workflows. What to Watch Adoption of LuxSit and NovoBodies by SignalChem customers, expansion into additional assay and protein-fusion applications and whether Monod Bio signs further “Monod Inside” licensing partnerships with life-science tools and services companies. Primary Source Monod Bio / SignalChem Biotech licensing announcement Relevant Date 26 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Switchboard Health acquires Livara Health to add virtual musculoskeletal care

    The acquisition moves Switchboard beyond specialty-care navigation into direct care delivery by integrating Livara’s virtual-first, value-based MSK model, alongside more than $5 million in new financing. Switchboard Health has acquired Livara Health, combining its specialty referral and care-navigation platform with Livara’s virtual orthopaedic and musculoskeletal care model for health plans, providers and employers. Alongside the acquisition, Switchboard closed an oversubscribed equity financing of more than $5 million to support its expansion into care delivery and further growth. Field Content Alert Type Deal Companies Switchboard Health; Livara Health Deal Type Acquisition with concurrent equity financing Asset or Company Livara Health Therapy Area(s) Musculoskeletal care; Orthopaedics; Physical therapy Technology or Modality Virtual care; Value-based healthcare; Care navigation; Digital health Deal Value Acquisition terms were not disclosed. In conjunction with the transaction, Switchboard closed an oversubscribed equity financing of more than $5 million. The financing included existing Switchboard and Livara investors as well as new backers including First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures and Martin Ventures. (Switchboard Health) Development Stage Commercial Geography United States What Happened On 25 August 2026, Switchboard Health announced the acquisition of Livara Health, formerly known as SpineZone, a virtual-first MSK management company. Switchboard will integrate Livara’s virtual MSK programme into its referral-management and automated care-navigation platform, allowing provider and health-plan customers to enrol eligible patients directly into Livara care. The deal marks an expansion of Switchboard’s business model from connecting patients with specialty providers to also delivering care. (Switchboard Health) Why It Matters The acquisition gives Switchboard an established clinical-care capability rather than limiting its role to referral and navigation infrastructure. Livara combines care planning, virtual treatment and navigation using a multidisciplinary model involving physicians, physical therapists and psychosocial providers, including services for complex and higher-cost MSK patients. (Switchboard Health) Supporting Context Switchboard cites an independent 2024 Validation Institute review reporting that participants in Livara’s programme achieved a 43% reduction in musculoskeletal spending, driven largely by lower surgical utilisation. Switchboard also reported that patient volumes moving through its own platform have increased 500% over the past nine months, providing the commercial backdrop for its expansion into direct care delivery. (Switchboard Health) Strategic Rationale Switchboard can combine its existing referral-management infrastructure and provider relationships with Livara’s clinical MSK services, creating a more integrated pathway from patient identification and referral through virtual treatment. Livara gains access to Switchboard’s provider and health-plan distribution channels, potentially allowing its MSK model to reach a larger patient population. Potential Impact The combination could enable Switchboard to capture a larger part of the specialty-care pathway while giving health plans and risk-bearing providers a single platform for identifying, navigating and treating MSK patients. The commercial impact will depend on successful integration and adoption of Livara services across Switchboard’s existing customer base. Key Takeaway The Livara acquisition transforms Switchboard from primarily a specialty-care navigation platform into a company that can also directly deliver virtual MSK care. What to Watch Integration of Livara into Switchboard’s platform, adoption among existing provider and health-plan customers and how Switchboard deploys the $5 million-plus financing to expand its care-delivery capabilities. Primary Source Switchboard Health acquisition announcement Relevant Date 25 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Allegheny Health Network and START partner to expand early-phase cancer trials in Western Pennsylvania

    The collaboration will establish a START clinical trial site inside AHN’s Allegheny General Hospital, connecting patients across the region with START’s portfolio of nearly 1,000 active early-phase oncology studies. Allegheny Health Network (AHN) and The START Center for Cancer Research have entered a strategic collaboration to establish a new early-phase oncology clinical trial site within the AHN Cancer Center at Allegheny General Hospital in Pittsburgh. The site will become part of START’s international research network and provide AHN patients with local access to its portfolio of industry-sponsored early-phase cancer trials, reducing the need for patients to travel outside Western Pennsylvania to participate. Field Content Alert Type Deal Companies Allegheny Health Network (AHN); The START Center for Cancer Research (START) Deal Type Strategic clinical research collaboration Asset or Company New START early-phase oncology clinical trial site at the AHN Cancer Center Therapy Area(s) Oncology; Cancer Technology or Modality Early-phase clinical trials; Investigational oncology therapies Deal Value Financial terms were not disclosed. Development Stage Early-phase clinical development Geography Western Pennsylvania, United States What Happened On 25 August 2026, AHN and START announced a strategic collaboration to establish a dedicated START early-phase clinical trial site within the AHN Cancer Center at Allegheny General Hospital in Pittsburgh. The site will be fully integrated into START’s network and will have access to its global trial portfolio from launch. The collaboration combines START’s early-phase oncology research infrastructure with AHN’s existing cancer specialists and clinical-care network. (www.ahn.org) Why It Matters Patients in Western Pennsylvania have historically had limited local access to community-based early-phase oncology studies, potentially requiring travel to participate. Embedding a dedicated trial site within AHN means eligible patients can potentially access investigational treatments as part of their existing cancer-care pathway, reducing a practical barrier to trial participation. Pennsylvania records approximately 89,000 new cancer cases annually, according to the organisations. (www.ahn.org) Supporting Context AHN is a 16-hospital health system, while its Cancer Center employs more than 200 physicians and 500 oncology professionals across 24 affiliated oncology clinics and serves more than 20,000 new patients annually. START operates across 16 locations in the US and Europe, with more than 40 principal investigators and nearly 1,000 active studies. (www.ahn.org) Strategic Rationale START gains access to AHN’s substantial regional cancer population and established clinical infrastructure, extending its community-based trial network into Western Pennsylvania. AHN gains a dedicated early-phase research capability and access to START’s international portfolio of industry-sponsored trials, strengthening the range of investigational treatment opportunities it can offer patients. Potential Impact The collaboration could increase participation in early-phase oncology trials across Western Pennsylvania and neighbouring regions while giving biopharma sponsors another community-based site through which to recruit patients. Its impact will ultimately depend on the studies activated at the new centre, patient eligibility and enrolment. Key Takeaway AHN is bringing START’s early-phase oncology trial network directly into its flagship cancer centre, creating a new local route into investigational cancer studies for patients across Western Pennsylvania. What to Watch Opening of the new START site, the first studies activated at Allegheny General Hospital, patient enrolment levels and whether the partnership expands the range and volume of early-phase oncology trials available through AHN. Primary Source Allegheny Health Network / The START Center for Cancer Research (www.ahn.org) Relevant Date 25 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Ireland’s HSE agrees to fund Skyclarys after Biogen improves commercial offer

    The reimbursement decision clears the way for Irish patients with Friedreich’s ataxia to access the first treatment for the rare neurological disease, following prolonged negotiations over cost and clinical value. Ireland’s Health Service Executive (HSE) has approved reimbursement of Biogen’s Skyclarys (omaveloxolone) for people with Friedreich’s ataxia, reversing an earlier recommendation against public funding after Biogen submitted a substantially improved commercial offer. The final negotiated price remains confidential, but the decision follows a two-year access campaign and previous concerns that the medicine was not cost-effective at its proposed price. Field Content Alert Type Industry Update Topic Drug reimbursement; Market access Organisation(s) Health Service Executive (HSE); Biogen; National Centre for Pharmacoeconomics (NCPE) Affected Stakeholders People with Friedreich’s ataxia; neurologists; rare disease specialists; Irish healthcare system Therapy Area(s) Neurology; Rare disease Geography Ireland What Happened On 25 August 2026, the HSE approved reimbursement of Skyclarys (omaveloxolone) for people with Friedreich’s ataxia. The decision followed a substantially revised commercial proposal from Biogen that the HSE described as very different from the offer previously considered by its Drugs Group. The final price is commercially confidential. Health Minister Jennifer Carroll MacNeill asked the HSE to begin working with Biogen immediately to establish the process through which eligible patients can access treatment. (RTÉ) Why It Matters Skyclarys is the first treatment for Friedreich’s ataxia, a rare progressive neuromuscular disease affecting an estimated 200 people in Ireland. The reimbursement decision therefore moves the medicine from regulatory approval to publicly funded access for Irish patients, illustrating the separate roles played by marketing authorisation and national pricing and reimbursement decisions. (RTÉ) Supporting Context The decision represents a significant reversal in the medicine’s Irish reimbursement process. In December 2025, the NCPE recommended against reimbursement unless the price was reduced, and the HSE Drugs Group subsequently recommended against funding. Earlier estimates placed treatment at around €280,000 per patient annually, with a five-year budget impact of more than €130 million. Biogen subsequently made a substantially improved financial offer, although the final negotiated figure has not been disclosed. (RTÉ) Who Is Most Affected People living with Friedreich’s ataxia in Ireland are the immediate beneficiaries. Patients and families had campaigned for access for around two years, arguing that delays were particularly significant for a progressive disease in which lost neurological function may not be recoverable. (RTÉ) Industry Impact The case highlights the market-access challenge surrounding high-cost medicines for small rare-disease populations. It also demonstrates how confidential price negotiations can alter a reimbursement outcome even after an initial negative health-economic assessment, while prompting wider debate in Ireland about the speed of its reimbursement pathway for orphan medicines. (RTÉ) Key Takeaway HSE reimbursement turns Skyclarys’ existing regulatory approval into a route to funded patient access in Ireland after Biogen substantially improved its commercial offer. What to Watch The timing and eligibility arrangements for patient access are now the immediate next steps, with the HSE and Biogen expected to work together to make treatment available as quickly as possible. (RTÉ) Primary Source RTÉ News – HSE reimbursement decision Relevant Date 25 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves first-in-class targeted therapy daraxonrasib for metastatic pancreatic cancer

    The approval introduces the first RAS(ON) inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with a KRAS G12X mutation, establishing a new biomarker-directed option for one of the hardest-to-treat cancers. The US Food and Drug Administration (FDA) has approved daraxonrasib for adults with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) whose tumours harbour a KRAS G12X mutation, making it the first approved RAS(ON) inhibitor and the first targeted therapy for this patient population. The decision establishes a new treatment option for patients whose disease has progressed following earlier systemic therapy and makes molecular testing for eligible KRAS mutations increasingly relevant to treatment selection. Field Content Alert Type Drug Approval Drug Name Daraxonrasib Indication Treatment of adults with previously treated metastatic pancreatic ductal adenocarcinoma harbouring a KRAS G12X mutation Therapy Area(s) Oncology; Pancreatic cancer Geography United States (FDA) What Happened The FDA has approved daraxonrasib, a first-in-class RAS(ON) inhibitor, for adults with previously treated metastatic PDAC whose tumours contain a KRAS G12X mutation. The approval establishes the first targeted treatment specifically available for this molecularly defined pancreatic cancer population. Daraxonrasib is designed to inhibit multiple oncogenic RAS variants in their active, or “ON”, state, distinguishing its mechanism from earlier mutation-specific KRAS inhibitors. Why It Matters KRAS alterations are found in the large majority of pancreatic ductal adenocarcinomas, but historically there have been few opportunities to directly target the underlying RAS biology. Approval of daraxonrasib provides a biomarker-directed treatment for a subset of patients with metastatic disease after prior therapy and represents an important clinical validation of targeting active RAS signalling in pancreatic cancer. Supporting Context Pancreatic cancer remains one of the most difficult solid tumours to treat, particularly once disease becomes metastatic. Daraxonrasib was developed to target active RAS proteins across several KRAS G12X variants rather than a single mutation, potentially allowing treatment of a broader molecular population than mutation-specific KRAS therapies. Patients must undergo appropriate molecular testing to determine whether their tumours carry an eligible KRAS G12X alteration. Key Takeaway Daraxonrasib’s approval establishes the first targeted therapy for KRAS G12X-mutated metastatic pancreatic cancer and marks the first regulatory approval for the RAS(ON) inhibitor class. What to Watch Commercial rollout and adoption of daraxonrasib, the effect of the approval on routine KRAS molecular testing in pancreatic cancer, and ongoing studies evaluating RAS(ON) inhibition in earlier treatment settings, additional tumour types and combination regimens. Primary Source US Food and Drug Administration Relevant Date 26 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page